Anabolic therapy for osteoporosis

International Journal of Fertility and Women's Medicine

Volumn 50, Issue 2, 2005, Pages 53-60

  Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

Author keywords

Bisphosphonates; Combination therapy; Human PTH(1 34); Monotherapy; Parathyroid hormone; Teriparatide; Toxicity (rat)

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

BONE TURNOVER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; MONOTHERAPY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; ANIMAL; BONE DENSITY; BONE REGENERATION; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; METABOLISM; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; CALCITONIN; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; TERIPARATIDE; TREATMENT OUTCOME; VITAMIN D;

EID: 33644673413     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. North American Menopause Society: Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 9:84-101, 2002.
2. Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712, 2004.
3. Borah B, Dufresne TE, Chmielewski PA, et al: Bone 34:736-746, 2004.
4. Black DM, Cummings SR, Karpf DB, et al: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541, 1996.
5. Harris ST, Watts NB, Genant HK, et al: Effects of rise-dronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352, 1999.
6. McClung MR, Geusens P, Miller PD, et al: Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340, 2001.
7. Harrington JT, Ste-Marie LG, Brandi ML, et al: Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129-135, 2004.
8. Bone HG, Hosking D, Devogelaer JP, et al: Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199, 2004.
9. Bilezikian JP, Silverberg SJ: Management of asymptomatic primary hyperparathyroidism. N Engl J Med 350:1746-1751, 2004.
10. Silverberg SJ, Shane E, de la Cruz L, et al: Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283-291, 1989.
11. Dobnig H, Turner RT: The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138:4607-4612, 1997.
12. Neer RM, Arnaud CD, Zanchetta JR, et al: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441, 2001.
13. Kurland ES, Cosman F, McMahon DJ, et al: Therapy of idiopathic osteoporosis in men with parathyroid hormone: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076, 2000.
14. Lindsay R, Nieves J, Formica C, et al: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350(9077):550-555, 1997.
15. Orwoll ES, Scheele WH, Paul S, et al: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17, 2003.
16. Rubin MR, Bilezikian JP: New anabolic therapies in osteoporosis. Endocrinol Metabol Clin North Am 32:285-308, 2003.
17. Dempster DW, Cosman F, Kurland ES, et al: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853, 2001.
18. Jiang Y, Zhao JJ, Mitlak BH, et al: Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941, 2003.
19. Zanchetta JR, Bogado CE, Ferretti JL, et al: Effects of teriparatide [recombinant human parathyroid hormone) 1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539-543, 2003.
20. Rehman Q, Lang TF, Arnaud CD, et al: Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int 14:77-81, 2003.
21. Rittmaster RS, Bolognese M, Ettinger MP, et al: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134, 2000.
22. Black DM, Greenspan SL, Ensrud KE, et al: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215, 2003.
23. Lane NE, Sanchez S, Modin GW, et al: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102(8):1627-1633, 1998.
24. Cosman F, Nieves J, Woelfert L, et al: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16(5):925-931, 2001.
25. Ettinger B, SanMartin JA, Crans G, et al: Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751, 2004.
26. Cosman F, Nieves JW, Luckey MM, et al: Daily versus cyclic PTH combined with alendronate versus alendronate alone for the treatment of osteoporosis. J Bone Miner Res 18(suppl 2);1120 (abstract), 2003.
27. Finkelstein JS, Hayes A, Hunzelman JL, et al: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226, 2003.
28. Cosman F, Nieves J, Woelfert L, et al: Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925-931, 2001.
29. Lindsay R, Scheele WH, Neer R, et al: Sustained vertebral fracture risk reduction after withdrawal of teri-paratide in postmenopausal women with osteoporosis. Arch Intern Med 164(18):2024-2030, 2004.
30. Kurland ES, Heller SL, Diamond B, et al: The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporosis Int 15:992-997, 2004.
31. Black DM, Rosen CJ, Palermo L, et al: The effect of 1 year of alendronate following 1 year of PTH(1-84): Second year results from the PTH and Alendronate (PaTH) trial N Engl J Med 2005 (in press).
32. Vahle JL, Sato M, Long GG, et al: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321, 2002.
33. Wilker CE, Jolette J, Smith SY, et al: A nonobservable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH(1-84) for 2 years: role of the C-terminal PTH receptor? [abstract]. Presented at the 26th meeting of the American Society for Bone and Mineral Research (ASBMR); October 1-5, 2004, Seattle, Washington.